You are here

Home » Content

ileri Yaşta Multipl Skleroz Tanısı Alan Bir Olgu

A Case with Diagnosed Multiple Sclerosis in Advanced Age

Journal Name:

  • Fırat Tıp Dergisi

Publication Year:

  • 2009

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Multiple sclerosis (MS) causes functional loss in different areas of central nervous system and, various clinical findings. Progress of MS could distinguish in same patient in different times as well as among different patients. We presented a female patient with diagnosed MS in 60 years old. Her complaints began in good clinical progress in young adult life. She had been observed prominent progression in clinical course after 58 years old. The aim of this article to discuss the choices of diagnosis and treatment in patients advanced ages.
Bookmark/Search this post with
Abstract (Original Language): 
Multipl skleroz (MS), merkezi sinir sisteminin farklı alanlarına ait işlev kaybına ve çok çeşitli klinik tablolara yol açabilen bir hastalıktır. Klinik tablolardaki heterojenite hastalığın seyrinde de göze çarpmaktadır. MS'in seyri hastadan hastaya ve aynı hastanın kendi klinik seyri içinde de farklılıklar gösterebilmektedir. Bu yazıda klinik belirtileri genç erişkin yaşta başlayan, ileri yaşa kadar nispeten iyi bir klinik seyri olan fakat 58 yaşından sonra klinik olarak belirgin kötüleşme gözlenen ve MS tanısını ilk olarak 60 yaşında alan bir olgu, ileri yaştaki hastalarda tanı ve tedavi seçeneklerini gözden geçirmek amacıyla tartışılmıştır.
FULL TEXT (PDF): 
PDF icon arastirmax-ileri-yasta-multipl-skleroz-tanisi-alan-bir-olgu.pdf
  • 4
293-296
  • Turkish

REFERENCES

References: 

1.
Erakso
y M, Akman Demir G. Merkezi Sinir Sisteminin myelin hastalıkları. Öge EA (Editör). Nöroloji:İ.Ü. İstanbul Tıp Fakültesi Temel ve Klinik Bilimler Ders Kitapları. 1.baskı, İstanbul: Nobel Tıp Kitabevleri 2004: 505-534.
2. Holmqvist P, Wallberg M, Hammar M, Landtblom AM, Brynhildsen J. Symptoms of multiple sclerosis in women in relation to sex steroid exposure. Maturitas 2006; 54 :149-153.
295
Fırat Tıp Dergisi 2009;14(4): 293-296
Kurt ve Ark.
3. Vukusic S, Hutchinson M, Hours M et al. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain 2004; 127(Pt 6):1353-1360.
4. Paavilainen T, Kurki T, Parkkola R et al. Magnetic resonance imaging of the brain used to detect early post-partum activation of multiple sclerosis. Eur J Neurol 2007; 14: 1216¬1221.
5. Saraste M, Vâisânen S, Alanen A, Airas L. Clinical and immunologic evaluation of women with multiple sclerosis during and after pregnancy. Gend Med 2007; 4:45-55.
6. Smith R, Studd JW. A pilot study of the effect upon multiple sclerosis of the menopause, hormone replacement therapy and the menstrual cycle. J R Soc Med 1992; 85: 612-613.
7. Tunalı G. Multipl sklerozda tanı kriterleri. Türkiye Klinikleri Nöroloji Dergisi 2004; 2: 205-209.
8. Martinelli V, Rodegher M, Moiola L, Comi G. Late onset multiple sclerosis: clinical characteristics, prognostic factors
and differential diagnosis. Neurol Sci 2004; 25 (Suppl 4): 350¬355.
9. de Seze J, Delalande S, Michelin E, et al. Brain MRI in late-onset multiple sclerosis. Eur J Neurol 2005;12: 241-244.
10. Vukusic S, Confavreux C. Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis. J Neurol Sci 2003; 206:135-137.
11. Ebers GC. Prognostic factors for multiple sclerosis: the importance of natural history studies. J Neurol 2005; 252
(Suppl 3):15-20.
12. Eraksoy M. .Multipl sklerozda immun modulatör tedaviler.
Türkiye
Klinikler
i Nöroloji Dergisi 2004; 2: 228-231.
13. Compston A, Coles A. Multiple sclerosis. Lancet 2002; 359(9313):1221-1231.
14. Rio J, Tintore M, Nos C et al. Interferon beta in secondary progressive multiple sclerosis: daily clinical practice. J Neurol
2007; 254: 849-853.
15. Scott LJ, Figgitt DP. Mitoxantrone: a review of its use in
multiple sclerosis. CNS Drugs 2004;18: 379-396.
16. Edan G, Miller D, Clanet M et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997; 62: 112-118.
17. Millefiorini E, Gasperini C, Pozzilli C et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J
Neurol 1997; 244:153-159.
18. Hartung HP, Gonsette R, König N et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360: 2018¬2025.
19. Tunalı G. Multipl sklerozda immunsupresyon tedavisi. Türki¬ye Klinikleri Nöroloji Dergisi 2004; 2: 223-227.

Thank you for copying data from http://www.arastirmax.com